Olaparib - promising direction in therapy in BRCA-associated tumors


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The results of clinical studies of the oral PARP inhibitor olaparib in patients with recurrent ovarian cancer and a number of other tumors are presented. The drug is indicated for patients with germline BRCA1 and BRCA2 gene mutations. Although these mutations are observed only in 10% of ovarian cancer cases, they represent a powerful risk factor for the development of this tumor. The frequency of response to olaparib in clinical studies is 26-40%. There is promising evidence of the use of olaparib for the treatment of metastatic HER2-negative breast cancer in patients with the germinal BRCA mutation and metastatic hormone-resistant prostate cancer.

Texto integral

Acesso é fechado

Sobre autores

M. Abramov

FSBINMRC of Oncology n.A. N.N. Blokhin of RMH

E. Chichikov

FSBINMRC of Oncology n.A. N.N. Blokhin of RMH

Email: e.chchkv@gmail.com
oncologist

E. Borisova

FSBINMRC of Oncology n.A. N.N. Blokhin of RMH

S. Gutorov

FSBINMRC of Oncology n.A. N.N. Blokhin of RMH

Bibliografia

  1. Alsop K., Fereday S., Meldrum C., deFazio A., Emmanuel C., George J., Dobrovic A., Birrer M.J., Webb R.M., Stewart C., Friedlander M., Fox S., Bowtell D., Mitchell G. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 2012;30(21):2654-63.
  2. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lui K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737): 245-51.
  3. Bookman M.A., Brady M.F., McGuire W.P., Harper P.G., Alberts D.S., Friedlander M., Colombo N., Fowler J.M., Argenta P.A., De Geest K., Mutch D.G., Burger R.A.,Swart A.M., Trimble E.L., Accario-Winslow C., Roth L.M. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 2009;27(9):1419-25.
  4. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P, Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-21.
  5. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichae I.J., Kaye S.B., Schellens J.H., de Bono J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009;361(2):123-34.
  6. Fong P.C., Yap T.A., Boss D.S., Carden C.P, Mergui-Roelvink M., Gourley C., De Greve J., Lubinski J., Shanley S., Messiou C., A'Hern R., Tutt A., Ashworth A., Stone J., Carmichael J., Schellens J.H., de Bono J.S., Kaye S.B. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 2010;28(15):2512-19.
  7. Girolimetti G., Perrone A.M., Santini D., Barbieri E., Guerra F., Ferrari S., Zamagni C., De Iaco P, Gasparre G., Turchetti D. BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed. Res. Int. 2014;2014:787143.
  8. Jelovac D., Armstrong D.K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 2011;61(3):183-203.
  9. Kaufman B.,Shapira-Frommer R.,Schmutzler R.K, Audeh M.W., Friedlander M., Balmaha J., Mitchell G., Fried G., Stemmer S.M., Hubert A., Rosengarten O., Steiner M., Loman N., Bowen K., Fielding A., Domchek S.M. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 2015;33(3):244-50.
  10. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C.L., Meier W., Shapira-Frommer R., Safra T., Matei D., Fielding A., Spencer S., Dougherty B., Orr M., Hodgson D., Barrett J.C., Matulonis U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61.
  11. Ledermann J.A., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., Matei D., Fielding A., Bennett B., Parry D., Spencer S., Mann H., Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br. J. Cancer. 2016;115(11):1313-20.
  12. Liu J.F., Barry W.T., Birrer M., Lee J.M., Buckanovich R.J., Fleming G.F., Rimel B., Buss M.K., Nattam S., Hurteau J., Luo W., Quy P, Whalen C., Obermayer L., Lee H., Winer E.P, Kohn E.C., Ivy S.P, Matulonis U.A. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207-14.
  13. Mateo J., Carreira S., Sandhu S., et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N. Engl. J. Med. 2015;373(18): 1697-708.
  14. Oza A.M., Cibula D., Benzaquen A.O., Poole C., Mathijssen R.H., Sonke G.S., Colombo N., Spacek J., Vuylsteke P., Hirte H., Mahner S., Plante M., Schmalfeldt B., Mackay H., Rowbottom J., Lowe E.S., Dougherty B., Barrett J.C., Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16(1):87-97.
  15. Reinbolt R.E., Hays J.L. The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies. Front. Oncol. 2013;3:237.
  16. Robson M., Im S.A., Senkus E., Xu B., Domchek S. M., Masuda N., Delaloge S., Li W., Tung N., Armstrong A., Wu W., Goessl C., Runswick S., Conte P. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 2017;377(6): 523-33.
  17. Rottenberg S., Jaspers J.E., Kersbergen A., van der Burg E., Nygren A.O., Zander S.A., Derksen P.W., de Bruin M., Zevenhoven J., Lau A., Boulter R., Cranston A., O'Connor M.J., Martin N.M., Borst P., Jonkers J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA. 2008;105(44):17079-84.
  18. Sehouli J., Stengel D., Oskay-Oezcelik G., Zeimet A.G., Sommer H., Klare P., Stauch M., Paulenz A., Camara O., Keil E., Lichtenegger W. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol. 2008;26(19): 3176-82.
  19. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016;66(1):7-30.
  20. Smith S.A., French T., Hollingsworth S.J. The impact of germline mutations on targeted therapy. J. Pathol. 2014;232(2):230-43.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies